Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Modern Rheumatology|May 20, 2009
A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugsJun Hashimoto, Patrick Garnero, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabNorihiro Nishimoto, Jun Hashimoto, Nobuyuki Miyasaka, et al.
Cytokine|March 14, 2003
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic miceAsao Katsume, Hiroyuki Saito, Yoshiki Yamada, et al.
Modern Rheumatology|December 13, 2019
Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in JapanMiho Murakami, Takeshi Johkoh, Seiji Hayashi, et al.
Modern Rheumatology|May 30, 2018
Predictive factors for structural remission using abatacept: Results from the ABROAD studyKosaku Murakami, Masahiro Sekiguchi, Shintaro Hirata, et al.
Modern Rheumatology|August 28, 2014
IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse modelMareki Ohtsuji, Qingshun Lin, Keiko Nishikawa, et al.
The Journal of Rheumatology|July 15, 2003
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical studyNorihiro Nishimoto, Kazuyuki Yoshizaki, Keiji Maeda, et al.
Modern Rheumatology|February 26, 2008
Characteristics of fracture and related factors in patients with rheumatoid arthritisAkihide Nampei, Jun Hashimoto, Junichiro Koyanagi, et al.
Modern Rheumatology|July 15, 2016
Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio studyNaoki Ishiguro, Tatsuya Atsumi, Masayoshi Harigai, et al.
Modern Rheumatology|June 15, 2007
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosusYoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, et al.
Pageof 12